Bull Harbor Capital LLC Makes New Investment in Becton, Dickinson and Company $BDX

Bull Harbor Capital LLC acquired a new stake in shares of Becton, Dickinson and Company (NYSE:BDX) in the 1st quarter, according to its most recent 13F filing with the SEC. The fund acquired 4,714 shares of the medical instruments supplier’s stock, valued at approximately $741,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Imprint Wealth LLC purchased a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at about $25,000. Steph & Co. raised its position in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after acquiring an additional 65 shares in the last quarter. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $29,000. Finally, WPG Advisers LLC lifted its stake in shares of Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

BDX has been the topic of several analyst reports. Piper Sandler dropped their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Evercore set a $180.00 target price on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. UBS Group assumed coverage on Becton, Dickinson and Company in a research report on Tuesday. They set a “buy” rating and a $190.00 target price on the stock. Barclays increased their price target on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Finally, Stifel Nicolaus cut their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research report on Thursday, May 7th. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $180.93.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This trade represents a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the sale, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,189 shares of company stock valued at $765,661. 0.40% of the stock is owned by corporate insiders.

Becton, Dickinson and Company Stock Down 1.7%

Shares of NYSE BDX opened at $165.59 on Friday. The firm has a market cap of $45.63 billion, a price-to-earnings ratio of 41.92, a price-to-earnings-growth ratio of 12.00 and a beta of 0.21. The company’s 50-day simple moving average is $151.48 and its 200-day simple moving average is $163.63. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The firm had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period last year, the company posted $3.35 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities analysts predict that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is presently 106.33%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.